BINDING OF NEU DIFFERENTIATION FACTOR WITH THE EXTRACELLULAR DOMAIN OF HER2 AND HER3

被引:64
|
作者
HORAN, T
WEN, J
ARAKAWA, T
LIU, NL
BRANKOW, D
HU, S
RATZKIN, B
PHILO, JS
机构
[1] Amgen Inc., Amgen Center, Thousand Oaks
关键词
D O I
10.1074/jbc.270.41.24604
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The interaction of neu differentiation factor (NDF) with the extracellular domains of Her2 (sHer2) and Her3 (sHer3) have been studied using native gels, light scattering, and sedimentation equilibrium. The full-length NDF beta 2 was shown to bind sHer3 with a dissociation constant of 26 +/- 9 nM, while it showed a 1000-fold weaker binding to sHer2. Taken together, these results demonstrate that NDF is a high affinity ligand for Her3, but not for Hera. No increase in affinity of the NDF beta 2 for sHer3 was observed upon addition of sHer2 to the NDF beta 2-sHer3 mixture. Binding of NDF beta 2 to sHer3 did not induce receptor dimerization or oligomerization, the stoichiometry being one sHer3 per one NDF molecule. This finding suggests that transmembrane and/or intracellular domains of receptor family members or perhaps additional unidentified components may be involved in NDF induced dimerization and autophosphorylation, or alternatively, that dimerization is not the mechanism for Her3 autophosphorylation and signal transduction.
引用
收藏
页码:24604 / 24608
页数:5
相关论文
共 50 条
  • [1] Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
    Xiu Li Zhang
    Yun Sheng Yang
    Dong Ping Xu
    Jian Hui Qu
    Ming Zhou Guo
    Yan Gong
    Jin Huang
    [J]. World Journal of Surgery, 2009, 33 : 2112 - 2118
  • [2] Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
    Zhang, Xiu Li
    Yang, Yun Sheng
    Xu, Dong Ping
    Qu, Jian Hui
    Guo, Ming Zhou
    Gong, Yan
    Huang, Jin
    [J]. WORLD JOURNAL OF SURGERY, 2009, 33 (10) : 2112 - 2118
  • [3] Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer
    Osipo, Clodia
    Meeke, Kathleen
    Cheng, Dong
    Weichel, Alyssa
    Bertucci, Anne
    Liu, Hong
    Jordan, V. Craig
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2007, 30 (02) : 509 - 520
  • [4] Identification of a heregulin binding site in HER3 extracellular domain
    Singer, E
    Landgraf, R
    Horan, T
    Slamon, D
    Eisenberg, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (47) : 44266 - 44274
  • [5] HEREGULIN-DEPENDENT REGULATION OF HER2/NEU ONCOGENIC SIGNALING BY HETERODIMERIZATION WITH HER3
    WALLASCH, C
    WEISS, FU
    NIEDERFELLNER, G
    JALLAL, B
    ISSING, W
    ULLRICH, A
    [J]. EMBO JOURNAL, 1995, 14 (17): : 4267 - 4275
  • [6] Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity
    Hanker, Ariella B.
    Brown, Benjamin P.
    Meiler, Jens
    Marin, Arnaldo
    Jayanthan, Harikrishna S.
    Ye, Dan
    Lin, Chang-Ching
    Akamatsu, Hiroaki
    Lee, Kyung-Min
    Chatterjee, Sumanta
    Sudhan, Dhivya R.
    Servetto, Alberto
    Brewer, Monica Red
    Koch, James P.
    Sheehan, Jonathan H.
    He, Jie
    Lalani, Alshad S.
    Arteaga, Carlos L.
    [J]. CANCER CELL, 2021, 39 (08) : 1099 - +
  • [7] HER-2/neu Gene Amplification in Relation to Expression of HER2 and HER3 Proteins in Patients With Esophageal Adenocarcinoma
    Yoon, Harry H.
    Sukov, William R.
    Shi, Qian
    Sattler, Christopher A.
    Wiktor, Anne E.
    Diasio, Robert B.
    Wu, Tsung-Teh
    Jenkins, Robert B.
    Sinicrope, Frank A.
    [J]. CANCER, 2014, 120 (03) : 415 - 424
  • [8] Co-occurring gain-of-function mutations in HER2 and HER3 cooperate to enhance HER2/HER3 binding, HER-dependent signaling, and breast cancer growth
    Hanker, A. B.
    Koch, J. P.
    Ye, D.
    Sliwoski, G.
    Sheehan, J.
    Kinch, L. N.
    Brewer, M. Red
    He, J.
    Miller, V. A.
    Lalani, A. S.
    Cutler, R. E., Jr.
    Croessmann, S.
    Zabransky, D. J.
    Meiler, J.
    Arteaga, C. L.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [9] Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity
    Hanker, Ariella B.
    Jayanthan, Harikrishna Sekar
    Ye, Dan
    Lin, Chang-Ching
    Akamatsu, Hiroaki
    Sheehan, Jonathan H.
    Koch, James P.
    Sudhan, Dhivya R.
    Brewer, Monica Red
    Servetto, Alberto
    He, Jie
    Miller, Vincent A.
    Lalani, Alshad S.
    Meiler, Jens
    Arteaga, Carlos L.
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [10] HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib
    Wehrenberg-Klee, Eric
    Sinevici, Nicoleta
    Nesti, Sarah
    Kalomeris, Taylor
    Austin, Emily
    Larimer, Benjamin
    Mahmood, Umar
    [J]. MOLECULAR IMAGING AND BIOLOGY, 2021, 23 (06) : 930 - 940